全球適體市場規模、佔有率、成長分析，依類型（核酸和胜肽）、依應用（診斷、治療）- 2024-2031 年產業預測

Global Aptamers Market Size, Share, Growth Analysis, By Type(Nucleic Acid and Peptide), By Application(Diagnostics, Therapeutics) - Industry Forecast 2024-2031

出版日期: 2024年04月02日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球適體市場規模為12.0億美元，預計將從2023年的1.43億美元成長到2031年的58.3億美元，預測期間（2024-2031年）複合年成長率為19.2%。

適配體因其在生產、純化和標靶藥物遞送方面的獨特優勢而引起了研究人員的極大興趣，與抗體相比具有分子尺寸小、免疫原性低、成本效益高、副作用少等優點。這刺激了適體開發的創新，有可能擴大市場。儘管存在各種遺傳變異，但目前的感染療法缺乏有效性，因此需要先進的解決方案。基於 SELEX 技術的診斷試劑盒有望生產高親和力中和劑，這可能會推動市場擴張。基於適配體的診斷試劑盒，與第二代基於DNA 適配體的適配體一樣，提供經濟高效的化學合成解決方案，例如EPIC 研究中使用的Soma Logic 的SomaScan Assay，可實現更深入的疾病了解並促進市場成長，以滿足日益成長的需求。基於適配體的診斷解決方案體積小、特異性高、選擇性高且功效高，是細胞層面疾病診斷的首選，可滿足到 2040 年癌症診斷的預期成長。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 歐洲其他地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 拉丁美洲其他地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- MEA 的其餘部分

競爭格局

前 5 名企業比較
2021 年關鍵參與者的市場定位
主要市場參與者所採取的策略
最佳制勝策略
近期市集活動
主要公司市佔率（%），2021年

主要公司簡介

NeoVentures Biotechnology Inc. (United States)
Base Pair Biotechnologies, Inc. (United States)
Aptagen, LLC (United States)
SomaLogic, Inc. (United States)
Vivonics, Inc. (United States)
Aptamer Sciences, Inc. (United States)
TriLink BioTechnologies, LLC (United States)
AMS Biotechnology Europe Ltd. (United Kingdom)
Aptamer Group Ltd. (United Kingdom)
NOXXON Pharma AG (Germany)
AM Biotechnologies, LLC (United States)
Aptus Biotech SL (Spain)
Aptamer Group (United Kingdom)
Ophthotech Corporation (United States)
Vivonics, Inc. (United States)
ATDBio Ltd. (United Kingdom)
Base Pair Biotechnologies, Inc. (United States)
Am Biotechnologies, LLC (United States)
Aptamer Sciences, Inc. (United States)
Orla Protein Technologies Ltd. (United Kingdom)
Archemix Corp. (United States)
AptaMatrix (United States)

簡介目錄

Product Code: SQMIG35E2038

Global Aptamers Market size was valued at USD 1.20 billion in 2022 and is poised to grow from 1.43 USD billion in 2023 to USD 5.83 billion by 2031, at a CAGR of 19.2% during the forecast period (2024-2031).

Aptamers have attracted significant interest from researchers due to their distinct advantages in production, purification, and targeted drug delivery, offering benefits such as small molecular size, low immunogenicity, cost-effectiveness, and reduced side effects compared to antibodies. This has spurred innovation in aptamer development, potentially expanding the market. Despite various genetic variations, current therapies for infections lack effectiveness, prompting the need for advanced solutions. SELEX technology-based diagnostic kits offer promise in producing high-affinity neutralizers, likely driving market expansion. Aptamer-based diagnostic kits, like the second-generation DNA aptamer-based Aptamer, offer cost-effective and chemically synthesized solutions, exemplified by Soma Logic's SomaScan Assay, utilized in the EPIC research, enabling deeper disease understanding and facilitating market growth to meet rising cancer diagnostic demands predicted by Cancer Research UK. With their small size, high specificity, selectivity, and efficacy, aptamer-based diagnostic solutions are preferred in cellular-level disease diagnosis, catering to the anticipated increase in cancer diagnoses by 2040.

Top-down and bottom-up approaches were used to estimate and validate the size of the global aptamers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Aptamers Market Segmental Analysis

Global Aptamers Market is segmented on the basis of type, application and region. By type, the market is segmented into nucleic acid and peptide. By application, market is segmented into diagnostics, therapeutics, research & development, others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Aptamers Market

Aptamers are integral to personalized medicine due to their ability to selectively bind to various target molecules like proteins, peptides, and small molecules. With the rising focus on tailored therapies and precision medicine, there's a heightened need for aptamers owing to their distinct benefits such as exceptional specificity, minimal immunogenicity, and customizable attributes. By facilitating precise molecular recognition, aptamers pave the way for the formulation of individualized treatment approaches, thereby playing a pivotal role in advancing personalized medicine strategies.

Restraints in the Global Aptamers Market

The advancement of the aptamers market faces obstacles due to intellectual property (IP) challenges, wherein patent rights and licensing agreements concerning aptamers and associated technologies may constrain their commercialization potential, particularly for specific applications or targets. The intricate IP landscape surrounding aptamer-based technologies introduces legal uncertainties and potential obstacles for market participants, impeding their growth prospects.

Market Trends of the Global Aptamers Market

The primary technique for aptamer selection, known as SELEX (Systematic Evolution of Ligands by Exponential Enrichment), is increasingly emphasizing optimization and automation to bolster efficiency, cut down expenses, and enhance the quality of aptamers. Innovations in high-throughput screening, microfluidics, and robotics are being harnessed to streamline the aptamer development workflow, thus democratizing and scaling up the process for wider accessibility.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Aptamers Market by Type

Market Overview
Nucleic Acid and Peptide

Global Aptamers Market by Application

Market Overview
Diagnostics
Therapeutics
Research & Development
Others

Global Aptamers Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

NeoVentures Biotechnology Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Base Pair Biotechnologies, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aptagen, LLC (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SomaLogic, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vivonics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aptamer Sciences, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
TriLink BioTechnologies, LLC (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AMS Biotechnology Europe Ltd. (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aptamer Group Ltd. (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NOXXON Pharma AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AM Biotechnologies, LLC (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aptus Biotech S.L. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aptamer Group (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ophthotech Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vivonics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ATDBio Ltd. (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Base Pair Biotechnologies, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Am Biotechnologies, LLC (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aptamer Sciences, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Orla Protein Technologies Ltd. (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Archemix Corp. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AptaMatrix (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments